Predictors of Nonseroconversion after SARS-CoV-2 Infection
Weimin Liu, Ronnie M. Russell, Frédéric Bibollet‐Ruche, Ashwin N. Skelly, Scott Sherrill-Mix, Drew A. Freeman, Regina Stoltz, Emily Lindemuth, Fang-Hua Lee, Sarah Sterrett, Katharine J. Bar, Nathaniel Erdmann, Sigrid Gouma, Scott E. Hensley, Thomas J. Ketas, Albert Cupo, Victor M. Cruz Portillo, John P. Moore, Paul D. Bieniasz, Théodora Hatziioannou, Greer Massey, Mary-Beth Minyard, Michael S. Saag, Randall S. Davis, George M. Shaw, William J. Britt, Sixto M. Leal, Paul Goepfert, Beatrice H. Hahn
Abstract
C oronavirus disease (COVID-19) is typically diag- nosed by reverse transcription PCR (RT-PCR) amplifi cation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA from nasopharyngeal fl uids (1). RT-PCR yields cycle threshold (C t ) values that are inversely correlated with viral loads (2) and thus provide an estimate of the number of SARS-CoV-2 RNA copies in the sample. Serologic assays complement COVID-19 diagnosis by documenting past infections. In most persons, binding and neutralizing antibodies develop within 1-3 weeks after onset of symptoms (3), and titers correlate with disease severity (4).